PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cviPermissionsJournals.ASM.orgJournalAEM ArticleJournal InfoAuthorsReviewers
 
Clin Vaccine Immunol. Aug 2011; 18(8): 1371–1377.
PMCID: PMC3147337
Vibrio cholerae O1 Infection Induces Proinflammatory CD4+ T-Cell Responses in Blood and Intestinal Mucosa of Infected Humans[down-pointing small open triangle]
Alison Kuchta,3 Taibur Rahman,3 Erica L. Sennott,1 Taufiqur R. Bhuyian,3 Taher Uddin,3 Rasheduzzaman Rashu,3 Fahima Chowdhury,3 Ashraf I. Kahn,3 Mohammad Arifuzzaman,3 Ana A. Weil,4 Michael Podolsky,1 Regina C. LaRocque,1,4 Edward T. Ryan,1,4,6 Stephen B. Calderwood,1,4,5# Firdausi Qadri,3# and Jason B. Harris1,2#*
1Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts
2Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
3International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh
4Department of Medicine, Harvard Medical School, Boston, Massachusetts
5Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts
6Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts
*Corresponding author. Mailing address: Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Phone: (617) 726-3812. Fax: (617) 726-7416. E-mail: jbharris/at/partners.org.
These authors made equal contributions.
#These authors share senior authorship and made equal contributions.
Received April 15, 2011; Revisions requested May 3, 2011; Accepted June 8, 2011.
Vibrio cholerae O1 is a noninvasive enteric pathogen and serves as a model for studies of mucosal immunity. Although symptomatic V. cholerae infection induces durable protection against subsequent disease, vaccination with oral killed whole-cell V. cholerae stimulates less long-lasting protection against cholera. In this study, we demonstrated that cholera induces an early proinflammatory cellular immune response that results in priming of Th1- and Th17-type cytokine responses to ex vivo antigenic stimulation and an increase in the ratio of Th1 to Th2 CD4+ T-cell responses. Comparable priming of Th1 and Th17 responses, with an increased ratio of Th1 to Th2 CD4+ T-cell responses, was not observed in subjects who received two doses of the oral cholera vaccine Dukoral (a whole-cell cholera toxin B subunit containing [WC-CTB] vaccine). These findings suggest that natural V. cholerae infection induces an early, proinflammatory cellular immune response, despite the apparent lack of clinical signs of inflammation. The failure of the WC-CTB vaccine to activate equivalent, CD4+ T-cell responses is a potential explanation for the shorter duration of protection following immunization with this vaccine. Additional studies are needed to determine whether these early T-cell-mediated events predict the subsequent duration of immunologic memory.
Vibrio cholerae causes 3 million to 5 million cases of diarrhea and over 100,000 deaths annually (2). Organisms colonize the epithelial surface of the small intestine and elaborate cholera toxin (CT), an essential virulence factor for all pandemic strains of V. cholerae (30). Because V. cholerae is a prototypical noninvasive pathogen, it serves as a model for the study of mucosal immunity (17).
Natural infection with V. cholerae provides greater than 90% protection against subsequent disease for at least 3 years in U.S. volunteer studies (the maximum period studied) and an average of 3 to 8 years on the basis of epidemiological studies in areas of endemicity (5, 19, 21). The mechanism(s) of protective immunity against cholera is not well understood but has been hypothesized to depend on anamnestic responses of memory B cells (16, 25, 35). Consistent with this, our group previously demonstrated that V. cholerae protein antigen-specific memory B cells remain detectable in the circulation for over a year following cholera, after circulating antibody levels have returned to baseline levels. In contrast, memory B-cell responses to lipopolysaccharide, a T-cell-independent antigen, were found to decrease more rapidly after infection (16). Such long-lasting memory B cells against V. cholerae protein antigens could play a role in mediating anamnestic responses and protection against subsequent infection.
In contrast, a currently licensed cholera vaccine, Dukoral (a whole-cell CT B subunit [WC-CTB] vaccine), consists of killed V. cholerae O1 supplemented with recombinant cholera toxin B subunit (rCTB) and provides over 60% protection. However, protection wanes by 3 years after vaccination, and the vaccine provides limited direct protection in children (6, 7). A second vaccine, licensed as Shanchol, is a bivalent preparation that includes a mixture of killed V. cholerae O1 as well as the O139 serogroup but does not include rCTB. The protective efficacy of this vaccine is greater than 65% over a 2- to 3-year observation period in India in all age groups, but longer-term protection has not yet been characterized (33). Recently, we observed that memory-B-cell responses against V. cholerae antigens were substantially less following vaccination with Dukoral than following natural infection, despite initially similar antibody-secreting cell and plasma antibody responses (1). Because of its toxicity, both licensed cholera vaccines lack the ADP-ribosylating cholera toxin A subunit (29).
Because of the critical role of CD4+ T cells in follicular B-cell differentiation, we hypothesized that the induction of CD4+ T-cell responses might be critical to the subsequent development of memory-B-cell responses and for long-term protective immunity following cholera. We have previously demonstrated that the proliferation of circulating CD4+ T cells in response to ex vivo stimulation with V. cholerae antigens peaks 7 days after cholera (3, 36), with the majority of these CD4+ T cells expressing both memory (CD45R0+ CD45RA) and gut-homing (α4β7) markers. Approximately 80% of these mucosal primed CD4+ T cells are CCR7 negative, and 20% are CCR7 positive, consistent with effector and central-memory phenotypes, respectively (36).
To better understand the phenotype of these effector CD4+ T-cell responses to V. cholerae infection and their role in subsequent memory development, we analyzed canonical lineage-specific cytokine responses of T cells to ex vivo stimulation with a V. cholerae membrane preparation (MP) after natural cholera and compared these to the responses seen following vaccination with the licensed WC-CTB vaccine.
Study design and subject enrollment.
Patients presenting to the hospital at the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B), with severe acute watery diarrhea with stool cultures positive for V. cholerae O1 were eligible for this study. Patients with significant comorbid conditions were excluded. Blood specimens were collected on the day after presentation (day 2) to allow for clinical stabilization and confirmation of a positive stool culture result. Adults from an unplanned urban area with demographic patterns similar to those observed in cholera patients and with no history of diarrhea during the previous 1 month were included as healthy controls. Additionally, healthy adult volunteers from a similar urban area were enrolled and vaccinated with two doses of the WC-CTB oral cholera vaccine on day 0 and day 14.
Because of the volume of blood required for the immunological assays, separate cohorts of patients, healthy controls, and vaccinees were enrolled for different components of the study. For the comparison of cytokine secretion in response to V. cholerae MP stimulation of whole blood, 7 patients and 5 vaccinees between the ages of 17 and 38 years were enrolled. The median age was 30 years in both groups. For the study of cytokine expression using intracellular cytokine staining/flow cytometry, 12 patients and 11 vaccinees between the ages of 16 and 50 years were enrolled. The median ages were 29 years in patients (mean, 29.9 ± 8.3 years) and vaccinees (28.6 ± 4.8 years) and 27 years in the control group (27.0 ± 5 years). A total of 14 cholera patients were enrolled in the endoscopy portion of the study for collection of duodenal pinch biopsy specimens. Specimens obtained from 5 healthy individuals with asymptomatic Helicobacter pylori infection enrolled in a separate and ongoing study were also utilized as controls. This cohort ranged in age from 22 to 45 years (median age, 30 years). All parts of this study were approved by the Research and Ethical Review Committee of the ICDDR,B and the Institutional Review Board of Massachusetts General Hospital, and all participants provided written informed consent. The human experimentation guidelines of the U.S. Department of Health and Human Services were followed during the conduct of this research.
Microbiologic examination of stools.
Stool from patients with a characteristic rice water appearance was plated directly on taurocholate-tellurite-gelatin agar for culture. After overnight incubation, suspected V. cholerae colonies were confirmed by slide agglutination with monoclonal antibodies to confirm the O1 serogroup and serotype. Recruitment of healthy controls and vaccinees was dependent on a negative stool screening for V. cholerae and enteric pathogens, including enterotoxigenic Escherichia coli, Salmonella, Shigella, and Campylobacter spp.
Stimulation of whole-blood cultures and measurement of cytokine production.
The methods for stimulation of whole-blood cultures and measurement of cytokine production used in these studies have been described previously (36). Briefly, venous blood was collected in lithium-heparin-coated tubes from patients on the second day of hospitalization (day 2) and again on days 7 and 30 after the onset of disease. Single blood samples were collected from the healthy controls. Venous blood from vaccinees was collected on the day of vaccination (day 0) and 7 days following each dose of vaccination (days 7 and 21). Whole blood was diluted 1:8 in Dulbecco modified Eagle medium supplemented with 1% gentamicin, 1% mercaptoethanol, and 10% heat-inactivated fetal calf serum (FCS). Then, 100 μl of stimulating antigen, V. cholerae MP (10 μg/ml) prepared from the V. cholerae O1 El Tor strain N16961 grown under toxin-inducing conditions, was added. The protein composition of V. cholerae MP was defined by mass spectroscopy and was previously described in detail (36). Phytohemagglutinin (PHA; 1.0 μg/ml) was used as a positive control, and nonstimulated cultures were used as negative controls. Culture supernatants obtained after 5 days of incubation at 37°C in 5% CO2 were used to measure concentrations of cytokines (gamma interferon [IFN-γ], interleukin-13 [IL-13], IL-17, IL-10) using a Milliplex human cytokine/chemokine kit following the manufacturer's recommended protocols (Millipore Corp., Billerica, MA). Although they are not uniquely expressed by a specific cell lineage, the cytokines IFN-γ, IL-13, IL-17, and IL-10 were chosen because they are among the canonical functional cytokines of major CD4+ T-cell subtypes (Th1, Th2, Th17, and regulatory T cells, respectively) and are expressed at high levels in these subsets.
Intracellular cytokine staining.
Peripheral blood mononuclear cells (PBMCs) and plasma were separated by differential centrifugation on Ficoll-Isopaque gradients (Pharmacia, Piscataway, NJ). PBMCs were resuspended at a concentration of 2 × 106 cells/ml in RPMI medium (Gibco, Carlsbad, CA) supplemented with 10% FCS (Gibco) and cultured in U-bottom tissue culture plates (Nunc, Denmark) in the presence of V. cholerae MP (10 μg/ml) or phorbol myristate acetate (PMA)-ionomycin at concentrations of 5 ng/ml and 1.0 μg/ml, respectively. Samples containing unstimulated cells were included as a negative control. Purified anti-CD28 (clone 28.2; BD Pharmingen) and anti-CD49d (clone 9F10; BD Pharmingen) at a concentration of 1.0 μg/ml were used for costimulation.
PBMCs and antigens were incubated for 2 h at 37°C in 5% CO2. After 2 h, brefeldin A (BFA; Sigma), (10 μg/ml) was added and cell cultures were incubated for an additional 4 h (15). Following the 6-h stimulation, cells were washed with phosphate-buffered saline (PBS) and 2% FCS. Washed pellets were stained for 30 min at 4°C with surface monoclonal antibodies: anti-CD3-fluorescein isothiocyanate (FITC) (clone SK7) and anti-CD4–peridinin-chlorophyll-protein complex (SK3; Becton Dickinson Immunocytometry Systems [BD], San Jose, CA). Following surface staining, cells were washed and then incubated with fluorescence-activated cell sorter (FACS) lysing solution (BD Bioscience, San Jose) for 10 min, washed, and then permeabilized with FACS permeabilizing solution (BD Bioscience, San Jose, CA) for 10 min at room temperature. Permeabilized cells were washed and then stained for 30 min at 4°C with fluorochrome-conjugated intracellular antibodies (i.e., anti IFN-γ, anti-IL-13, anti-IL-10, and anti-IL-17 phycoerythrin; BD Bioscience). Following staining, cells were washed and fixed in formaldehyde before flow cytometry was performed using a FACSCalibur apparatus (BD Bioscience) (15). The lymphocyte population was identified in a forward- versus side-scatter plot, and then the CD3+ CD4+ subpopulation was gated, followed by identification of the CD4+ cytokine-positive subpopulation. Net stimulation was calculated by subtracting the frequency of parental (FOP) of the nonstimulated cells from the FOP of the antigen-stimulated cells.
Duodenal biopsies, immunohistochemistry, and lamina propria lymphocyte cultures.
Pinch biopsy specimens 0.1 cm3 in size were obtained as described previously from the first part of the duodenum from selected study participants (28). A portion of the biopsy specimens was immediately fixed in 10% formalin in sodium phosphate buffer (4 g/liter monobasic and 6.5 g/liter dibasic; Fisher, Morris Plains, NJ), embedded in paraffin, and sectioned at 5 μm. Antigen retrieval was performed by heating the sections in a microwave oven in sodium citrate buffer (pH 6.0). The sections were incubated with antibody against IL-17 (Santa Cruz Biotechnology, Santa Cruz, CA). Horseradish peroxidase-conjugated mouse anti-rabbit antibody was used as the secondary reagent, and the sections were developed with diaminobenzidine as the substrate. The sections were counterstained with hematoxylin, dehydrated, and mounted. QWin software (Leica Microsystems, Switzerland) with the Leica (DMLB) microscope was used for measuring the intensity of the IL-17-positive area. The intensity of IL-17 staining was analyzed using an acquired computerized image analysis (ACIA) score. This metric has been described previously and is defined as the total positively stained area measured times the mean intensity of the positive area divided by the total area measured, including both negatively or positively stained tissues (31).
Another biopsy specimen was used for extraction of lamina propria lymphocytes (LPLs), as described previously (4). Biopsy specimens were washed in PBS and Hank's balanced salts solution (HBSS; H4641; Sigma) and then incubated with EDTA (1 mM) and dithiothreitol (1 mM) with gentle vortexing. Supernatants were pooled and filtered through nylon mesh to obtain the intraepithelial cell fraction. This fraction was washed, resuspended, and incubated in RPMI medium with 5 ml of collagenase and DNase (100 U/ml and 0.1 mg/ml, respectively; C0255 and D5025, respectively; Sigma) solution for 2 h at 37°C. This cell suspension was filtered through nylon mesh cloth, and the LPL fraction was resuspended in RPMI medium and placed in 24-well cell culture plates (BD Biosciences). Plates were incubated at 37°C in 5% CO2 for 5 days. Culture supernatants were used to obtain the concentrations of cytokines (IL-6, IL-17, and IL-1β) using a Milliplex human cytokine/chemokine kit following the manufacturer's recommended protocols (Millipore Corp., Billerica, MA). The concentration of IL-8 was measured using a human CXCL8/IL-8 DuoSet kit following the manufacturer's recommended protocol (R&D Systems, Inc., Minneapolis, MN). Transforming growth factor β1 (TGF-β1) concentrations were measured using a Milliplex human TGF-β1 kit following the manufacturer's recommended protocols (Millipore Corp).
Statistical analyses.
To measure the statistical significance of the observed cytokine responses, the Mann-Whitney U test was used to evaluate comparisons of immune responses between groups of patients, vaccinees, and healthy controls. The Wilcoxon test was used to compare responses within groups at different time points. To evaluate trends in the immune responses after one and two doses of vaccine, a nonparametric trend test was used (9). A two-tailed P value of ≤0.05 was considered the cutoff for a significant difference.
Cytokine responses to ex vivo V. cholerae antigens in cell culture supernatants.
To compare the cytokine responses to V. cholerae antigen stimulation of circulating T cells in patients with cholera and in recipients of the WC-CTB vaccine, we measured the concentrations of IFN-γ, IL-10, IL-13, and IL-17 in supernatants collected from cultures of whole blood, stimulated by the addition of V. cholerae MP, using methods described previously (34, 36). Cytokine levels were compared in patients and vaccinees in response to antigenic stimulation; unstimulated whole blood and PHA-stimulated whole blood were used as negative and positive controls, respectively.
As shown in Fig. 1, cholera patients demonstrated a significant increase in production of IFN-γ and IL-17 in response to ex vivo stimulation with V. cholerae MP. There was also a trend toward an increase in IL-13 in V. cholerae MP-primed cells (P = 0.06). There was no significant increase seen in IL-10. Similarly, there were no significant differences in cytokine levels in the unstimulated controls (see Fig. S2 in the supplemental material) or the PHA-stimulated controls at different time points, indicating that the priming of IFN-γ and IL-17 secretion in peripheral blood demonstrated on day 7 was V. cholerae antigen specific (see Fig. S1 in the supplemental material). The increased IFN-γ response to V. cholerae antigen stimulation remained detectable in the peripheral circulation through day 30 after infection. In contrast, subjects who received the WC-CTB vaccine did not develop a significant increase in IFN-γ, IL-13, or IL-17 production in response to ex vivo stimulation of whole blood with V. cholerae MP. There was a modest trend suggestive of increasing IL-10 responses after two doses of the cholera vaccine, but this did not reach statistical significance (P = 0.10).
Fig. 1.
Fig. 1.
Infection but not WC-CTB vaccination induces adaptive IFN-γ, IL-13, and IL-17 responses. Cytokine responses to ex vivo stimulation of whole blood by V. cholerae MP were measured in cholera patients and WC-CTB vaccine recipients. Blood was collected (more ...)
Cytokine responses of specific V. cholerae antigen-stimulated CD4+ T-cell populations.
Because the measurement of cytokine concentrations in cell culture supernatants does not distinguish the precise cellular origin of individual cytokines, we also performed flow cytometry-based intracellular cytokine staining (ICS) on PBMCs stimulated with V. cholerae MP to compare the proportions of individual CD4+ T cells expressing cytokines characteristic of Th1 (IFN-γ) and Th2 (IL-13) lineages.
Previous studies have focused on the ratio of Th1/Th2 responses as an important determinant of the mucosal immune response (12, 13, 26). As shown in Fig. 2 C, infection with V. cholerae resulted in a shift toward a Th1 to Th2 response to V. cholerae MP stimulation, with a >2 fold increase in the ratio of IFN-γ-expressing/IL-13-expressing CD4+ T cells on day 7 following cholera compared to the ratios on day 2 (P = 0.008) as well compared to the ratios for healthy controls (P < 0.001). In contrast, no change in the ratio of CD4+ T cells expressing IFN-γ/IL-13 in response to stimulation with V. cholerae MP was seen at any time point after vaccination compared to the baseline measurement (P = 0.248 at day 7 and P = 0.203 on day 21). Furthermore, no change in the ratio of IFN-γ-expressing/IL-13-expressing cells was seen in patients or vaccinees in response to PHA stimulation, indicating that the increased Th1 and Th2 response observed in patients was specific to V. cholerae antigenic stimulation.
Fig. 2.
Fig. 2.
Infection but not vaccination results in a shift toward Th1 to Th2 CD4+ T-cell responses. The relative proportions of CD4+ T cells expressing IFN-γ/IL-13 in response to ex vivo stimulation by V. cholerae MP were measured in cholera patients and (more ...)
Confirmation of a mucosal IL-17 response in cholera patients.
Cholera is a prototypical noninvasive noninflammatory diarrheal illness, and therefore, we had not anticipated a significant IL-17 response to V. cholerae antigen stimulation in peripheral blood of cholera patients. To confirm the induction of Th17 responses in mucosal tissues in cholera patients, we performed immunohistochemistry to examine IL-17 expression in duodenal biopsy specimens of patients recovering from cholera. As shown in Fig. 3, increased expression of IL-17 in situ was demonstrated in the lamina propria during acute cholera (day 2) compared to the expression on subsequent days and in control subjects, suggesting that infection with V. cholerae induces mucosal Th17 responses in lamina propria cells during the acute phase of illness that can subsequently be detected in the circulation by measuring responses of CD4+ T cells to V. cholerae antigenic stimulation.
Fig. 3.
Fig. 3.
Natural infection with V. cholerae O1 induces a mucosal IL-17 response. Duodenal biopsy specimens were stained for IL-17 expression, and the distribution and intensity of staining were compared in healthy controls (HC; n = 5) and cholera patients (n = (more ...)
We further recovered LPLs from duodenal biopsy specimens obtained immediately during acute illness (day 2), later in convalescence (day 30), and in healthy controls. LPL cell culture supernatants were used to measure cytokine expression, as cytokines secreted by the cultured LPLs on day 2 likely reflect the functional phenotype of these cells stimulated in vivo during V. cholerae O1 infection. As shown in Fig. 4, there was a trend toward an elevation of IL-17 in acute cholera (P = 0.07 compared to day 30, P = 0.09 compared to healthy controls), as well as increases in other proinflammatory cytokines, including IL-6 (P = 0.007 compared to day 30, P = 0.04 compared to healthy controls), which, along with TGF-β, is essential for the initial development of Th17 responses. Despite the lack of a clinically significant systemic inflammatory response in cholera, IL-8 was also increased during acute illness (P = 0.032 compared to day 30). In contrast, TGF-β was expressed by LPLs at similar levels in acute- and convalescent-phase cholera samples.
Fig. 4.
Fig. 4.
Infection with V. cholerae O1 induces mucosal IL-17, IL-6, IL-1β, and IL-8 responses. Cytokines (IL-17, IL-6, IL-1β, TGF-B1, and IL-8) excreted by unstimulated cultured lamina propria lymphocytes from duodenal biopsy specimens of cholera (more ...)
Infection with V. cholerae provides long-term protection against subsequent disease (5, 19, 21). Although the mechanism(s) of protective immunity is not well understood, protection may be mediated by anamnestic immune responses to V. cholerae antigens (16, 25, 35). In support of this, memory-B-cell responses to V. cholerae protein antigens remain detectable for at least 1 year after infection, longer than circulating antibodies or circulating memory-B-cell responses to V. cholerae O1 lipopolysaccharide (16). Because helper T cells play a critical role in the development of long-lived memory B cells directed against protein antigens (8), we have hypothesized that the initial CD4+ T-cell response to V. cholerae infection may contribute to long-term protection against cholera.
Previously, we observed that patients recovering from cholera develop gut-homing central and effector memory CD4+ T-cell immune responses to V. cholerae protein antigens that peak in the circulation 7 days after cholera (3, 36). In this study, we characterized the functions of the cellular immune responses to V. cholerae O1 in cholera patients and vaccinees by measuring the lineage-specific CD4+ T-cell responses to ex vivo antigenic stimulation.
The paradigmatic cellular immune response to mucosal infection involves Th2-regulated IgA production; however, there are examples where Th1 or Th17 responses may be critical determinants of protective immunity against potentially invasive mucosal pathogens (12, 13, 23, 26). Because cholera is prototypical of a noninflammatory, toxin-mediated diarrhea (17), it was plausible that the disease would induce a CD4+ T-cell response skewed predominantly toward a noninflammatory Th2 response to V. cholerae antigens.
However, the findings of this study do not support this hypothesis. Instead, infection with V. cholerae primed Th1 and Th17 responses, with a shift toward Th1 to Th2 CD4+ T-cell responses. Despite the absence of overt pyogenic infection and gross histological changes in the gut during cholera, these responses are preceded by a mucosal innate immune response to infection that includes increases in IL-1β, IL-6, and IL-8 secretion by lamina propria lymphocytes. These results are consistent with increasing evidence that early responses to V. cholerae O1 infection include the upregulation of expression of proteins with presumed bacterial inhibitory properties, including lactoferrin and long palate, lung, and nasal epithelium clone 1 (LPLUNC1) (14, 28), and the migration of neutrophils to the lamina propria and epithelium during acute cholera (14, 28). It was previously shown that IL-1β expression is increased during acute cholera, a finding reproduced in this study. However, the finding that IL-6, a critical bridge between innate and adaptive immunity through the promotion of B-cell IgA class switch differentiation and T-cell differentiation (Th17 lineage), was increased in acute cholera is an extension of these findings with potential implications for the development of long-term immunologic memory.
Despite the similar antigenic composition of the WC-CTB vaccine and live V. cholerae O1 organisms encountered in natural infection, we observed significant differences in the CD4+ T-cell response in cholera patients and vaccinees. Compared to natural infection with V. cholerae O1, vaccination resulted in limited priming of cellular immune responses to V. cholerae antigens. In addition, while subjects recovering from cholera developed a shift toward increased Th1/Th2 CD4+ T-cell responses, a comparable shift in the Th1/Th2 ratio of T-cell cytokine production was not observed in subjects who received two doses of the vaccine.
The finding that natural cholera induces proinflammatory CD4+ T-cell responses greater than those seen in WC-CTB vaccine recipients is consistent with in vitro and murine models of the mechanisms of the adjuvant effects of CT holotoxin. In mice, the effectiveness of CT as an adjuvant is dependent on the presence of CD4+ T cells (18). The CT holotoxin induces a broad spectrum of CD4+ T-cell responses, including Th1, Th2, Th17, and regulatory T-cell responses, to coadministered antigens (20, 22). Recent evidence, also from a murine model, suggests that the induction of Th17 responses is essential for the mucosal adjuvant activity of CT holotoxin; specifically, the induction of an IL-17 response by CT is required to generate protective mucosal IgA antibody responses to coadministered antigens (11). Our clinical observations here similarly demonstrate that humans with natural cholera (and, hence, exposure to CT holotoxin) also develop V. cholerae antigen-specific mucosal IL-17 responses, despite the absence of overt pyogenic infection.
In contrast to the adjuvant effect of the CT holotoxin, the mucosal application of only CTB, the GM1 ganglioside-binding portion of the toxin, results in the differentiation of both adaptive and natural regulatory T cells that produce IL-10 and suppress Th1, Th2, and Th17 responses and promote tolerance to coadministered antigens (10, 22, 32). Thus, the presence of CTB in the WC-CTB vaccine may provide a possible mechanism by which vaccine-induced CD4+ T-cell responses to V. cholerae MP may be diminished or skewed toward the development of a Th2 T-cell phenotype. This may also explain why in initial clinical trials, the protective efficacy of the whole-cell-only vaccine (without CTB) against cholera was more persistent and ultimately afforded protection that exceeded the protection afforded by the WC-CTB vaccine by the third year of follow-up (62% for the whole-cell-only vaccine compared to 40% for the WC-CTB vaccine) (6, 7). Because the more recently licensed Shanchol vaccine does not include CTB, it may elicit a different profile of cellular immune responses to V. cholerae protein antigens than the WC-CTB vaccine and requires additional study.
In this study, we observed robust CD4+ T-cell immune responses in cholera patients that fell outside the predicted model for a noninvasive mucosal infection. However, in future studies, it will be critical to gauge the significance of these early CD4+ T-cell responses to V. cholerae. Because memory-B-cell responses to protein antigens persist longer than serum antibody responses, it may be useful to evaluate the association between early T-cell responses and the subsequent development and maintenance of long-term memory B cells. In addition, future studies are needed to examine the role of the CXCR5-expressing follicular helper T cells, which likely play a particularly important role in regulating B-cell proliferation and class switching (24, 27). These studies may help further define the role of early T-cell responses in determining longlasting immunity to cholera.
ACKNOWLEDGMENTS
This research was supported by the ICDDR,B Centre for Health and Population Research and by the following grants: International Research Scientist Development Award KO1 TW07409 (to J.B.H.), U01 AI058935 (to S.B.C.), RO3 AI063079 (to F.Q.), and U01 AI077883 (to E.T.R.); International Research Scientist Development Award KO1 TW07144 (to R.C.L.); a Charles H. Hood Foundation award (to J.B.H.); a Howard Hughes Medical Institute Physician Scientist Early Career Award (to R.C.L.); and Fogarty International Center Global Infectious Disease Research Training Program Award in Vaccine Development D43 TW05572 (to M.A.). A.K., A.A.W., F.C., and A.I.K. are recipients of Fogarty International Clinical Research Scholars awards from the Fogarty International Center at the National Institutes of Health (D43 TW005572 and R24 TW007988). F.Q. and T.R.B. are recipients of funds from the Swedish Agency for International Development and Cooperation (Sida).
Footnotes
Supplemental material for this article may be found at http://cvi.asm.org/.
[down-pointing small open triangle]Published ahead of print on 22 June 2011.
1. Alam M. M., et al. 2011. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 18:844–850. [PMC free article] [PubMed]
2. 2010. Cholera vaccines: WHO position paper. Wkly. Epidemiol. Rec. 85:117–128. [PubMed]
3. Bhuiyan T. R., et al. 2009. Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation. Infect. Immun. 77:1888–1893. [PMC free article] [PubMed]
4. Bhuiyan T. R., et al. 2008. Comparison of mucosal B- and T-cell responses in Helicobacter pylori-infected subjects in a developing and a developed country. FEMS Immunol. Med. Microbiol. 54:70–79. [PubMed]
5. Cash R. A., et al. 1974. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J. Infect. Dis. 130:325–333. [PubMed]
6. Clemens J. D., et al. 1988. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 158:60–69. [PubMed]
7. Clemens J. D., et al. 1990. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270–273. [PubMed]
8. Crotty S., Ahmed R. 2004. Immunological memory in humans. Semin. Immunol. 16:197–203. [PubMed]
9. Cuzick J. 1985. A Wilcoxon-type test for trend. Stat. Med. 4:87–90. [PubMed]
10. D'Ambrosio A., Colucci M., Pugliese O., Quintieri F., Boirivant M. 2008. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J. Leukoc. Biol. 84:661–668. [PubMed]
11. Datta S. K., et al. 2010. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc. Natl. Acad. Sci. U. S. A. 107:10638–10643. [PubMed]
12. Davenport V., Groves E., Hobbs C. G., Williams N. A., Heyderman R. S. 2007. Regulation of Th-1 T cell-dominated immunity to Neisseria meningitidis within the human mucosa. Cell. Microbiol. 9:1050–1061. [PubMed]
13. Davenport V., et al. 2008. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J. Infect. Dis. 198:731–740. [PubMed]
14. Flach C. F., et al. 2007. Broad up-regulation of innate defense factors during acute cholera. Infect. Immun. 75:2343–2350. [PMC free article] [PubMed]
15. Gauduin M. C. 2006. Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses. Methods 38:263–273. [PubMed]
16. Harris A. M., et al. 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun. 77:3850–3856. [PMC free article] [PubMed]
17. Holmgren J., Czerkinsky C. 1992. Cholera as a model for research on mucosal immunity and development of oral vaccines. Curr. Opin. Immunol. 4:387–391. [PubMed]
18. Hornquist E., Grdic D., Mak T., Lycke N. 1996. CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin. Immunology 87:220–229. [PubMed]
19. Koelle K., Rodo X., Pascual M., Yunus M., Mostafa G. 2005. Refractory periods and climate forcing in cholera dynamics. Nature 436:696–700. [PubMed]
20. Lee J. B., Jang J. E., Song M. K., Chang J. 2009. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 4:e5190. [PMC free article] [PubMed]
21. Levine M. M., et al. 1981. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:818–820. [PubMed]
22. Lycke N. 2005. Targeted vaccine adjuvants based on modified cholera toxin. Curr. Mol. Med. 5:591–597. [PubMed]
23. Malley R., et al. 2006. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect. Immun. 74:2187–2195. [PMC free article] [PubMed]
24. McHeyzer-Williams L. J., Pelletier N., Mark L., Fazilleau N., McHeyzer-Williams M. G. 2009. Follicular helper T cells as cognate regulators of B cell immunity. Curr. Opin. Immunol. 21:266–273. [PMC free article] [PubMed]
25. Nelson E. J., Harris J. B., Morris J. G., Jr., Calderwood S. B., Camilli A. 2009. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat. Rev. Microbiol. 7:693–702. [PubMed]
26. Neurath M. F., Finotto S., Glimcher L. H. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8:567–573. [PubMed]
27. Nurieva R. I., Chung Y. 2010. Understanding the development and function of T follicular helper cells. Cell. Mol. Immunol. 7:190–197. [PubMed]
28. Qadri F., et al. 2004. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 53:62–69. [PMC free article] [PubMed]
29. Ryan E. T., Calderwood S. B., Qadri F. 2006. Live attenuated oral cholera vaccines. Expert Rev. Vaccines 5:483–494. [PubMed]
30. Sack D. A., Sack R. B., Nair G. B., Siddique A. K. 2004. Cholera. Lancet 363:223–233. [PubMed]
31. Sarker P., et al. 2010. Differential expression of enteric neuroimmune-network in invasive and acute watery diarrhoea. Neurogastroenterol. Motil. 22:70–78, e29. [PubMed]
32. Sun J. B., Czerkinsky C., Holmgren J. 2010. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 71:1–11. [PubMed]
33. Sur D., et al. 2009. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374:1694–1702. [PubMed]
34. Svahn A., et al. 2003. Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J. Immunol. Methods 277:17–25. [PubMed]
35. Svennerholm A. M., et al. 1984. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149:884–893. [PubMed]
36. Weil A. A., et al. 2009. Memory T-cell responses to Vibrio cholerae O1 infection. Infect. Immun. 77:5090–5096. [PMC free article] [PubMed]
Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of
American Society for Microbiology (ASM)